Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1501 AL 1515

Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases

Cauwe B, Opdenakker G.

Crit Rev Biochem Mol Biol. 2010 Oct;45(5):351-423. doi: 10.3109/10409238.2010.501783.

The roles of TNF in brain dysfunction and disease

Clark IA, Alleva LM, Vissel B.

Pharmacol Ther. 2010 Dec;128(3):519-48. doi: 10.1016/j.pharmthera.2010.08.007. Epub 2010 Sep 8.

Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders

Zabel C, Nguyen HP, Hin SC, Hartl D, Mao L, Klose J.

J Proteomics. 2010 Oct 10;73(11):2230-8. doi: 10.1016/j.jprot.2010.08.008. Epub 2010 Sep 8.

[How to manage daytime sleepiness associated with Parkinson's disease]

De Cock VC, Dauvilliers Y.

Rev Neurol (Paris). 2010 Oct;166(10):793-9. doi: 10.1016/j.neurol.2010.07.015. Epub 2010 Sep 1.

Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease

Rajapakse S, Abeynaike L, Wickramarathne T.

J Clin Psychopharmacol. 2010 Oct;30(5):620-2. doi: 10.1097/JCP.0b013e3181ee2ae7.

Effects of remifentanil anesthesia on cardiac electrophysiologic properties in children undergoing catheter ablation of supraventricular tachycardia

Niksch A, Liberman L, Clapcich A, Schwarzenberger JC, Silver ES, Pass RH.

Pediatr Cardiol. 2010 Oct;31(7):1079-82. doi: 10.1007/s00246-010-9768-8. Epub 2010 Sep 3.

Selective degradation of p62 by autophagy

Ichimura Y, Komatsu M.

Semin Immunopathol. 2010 Dec;32(4):431-6. doi: 10.1007/s00281-010-0220-1. Epub 2010 Sep 3.

[Sirtuins--modulation of their activity as a novel therapeutic target]

Kucińska M, Piotrowska H, Murias M.

Pol Merkur Lekarski. 2010 Mar;28(165):231-5.

Management of motor complications in Parkinson disease: current and emerging therapies

Espay AJ.

Neurol Clin. 2010 Nov;28(4):913-25. doi: 10.1016/j.ncl.2010.03.014.

Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?

Senard JM, Pathak A.

Rev Neurol (Paris). 2010 Oct;166(10):779-84. doi: 10.1016/j.neurol.2010.07.007.

["Red flags": when to be alerted and how to explore?]

Tison F.

Rev Neurol (Paris). 2010 Oct;166(10):775-8. doi: 10.1016/j.neurol.2010.07.009.

[Parkinson's disease: Role of genetic and environment factors. Involvement in everyday clinical practice]

Defebvre L.

Rev Neurol (Paris). 2010 Oct;166(10):764-9. doi: 10.1016/j.neurol.2010.07.014.

Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis

Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, Schiesling C, Schulte C, Sharma M, Illig T, Bauer P, Jung S, Nordheim A, Schöls L, Riess O, Krüger R.

Hum Mol Genet. 2010 Nov 15;19(22):4437-52. doi: 10.1093/hmg/ddq370. Epub 2010 Sep 2.

Inflammation in neurological disorders: a help or a hindrance?

Wee Yong V.

Neuroscientist. 2010 Aug;16(4):408-20. doi: 10.1177/1073858410371379.

Nitric oxide signaling in brain function, dysfunction, and dementia

Steinert JR, Chernova T, Forsythe ID.

Neuroscientist. 2010 Aug;16(4):435-52. doi: 10.1177/1073858410366481.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias